Lieff Cabraser files securities class action against ImmunityBio alleging misleading claims about Anktiva; investors (1/19–3/24/2026) urged to act, lead plaintiff deadline May 26, 2026.Abstract: Lieff Cabraser announced a securities class action against ImmunityBio (IBRX) alleging misrepresentation of Anktiva's capabilities, tied to an FDA warning and a stock drop; targets investors who bought between January 19 and March 24, 2026, with a lead-plaintiff deadline of May 26, 2026.

NodeGuardian

2026-04-21 15:01:09

Abstract generation in progress

National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP has announced a securities class action lawsuit against ImmunityBio, Inc. (IBRX). Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, are encouraged to contact the firm, with a lead plaintiff deadline set for May 26, 2026. The lawsuit alleges that ImmunityBio’s Executive Chairman, Patrick Soon-Shiong, misrepresented the capabilities of their bladder cancer drug Anktiva, leading to a significant stock drop after a U.S. FDA warning letter cited misleading promotional claims.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
300.8K Popularity
#
Gate13thAnniversaryLive
760.16K Popularity
#
BitcoinBouncesBack
174.49K Popularity
#
USIranTalksProgress
880.39K Popularity
#
HKUnveilsNewCryptoRules
275.22K Popularity

Sitemap

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class Action - Contact Lieff Cabraser

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

BitcoinBouncesBack

USIranTalksProgress

HKUnveilsNewCryptoRules

Pin